Pharmacyte Stock Buy Hold or Sell Recommendation

PMCB -  USA Stock  

USD 2.22  0.05  2.20%

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Pharmacyte Biotech is 'Buy'. Macroaxis provides Pharmacyte Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PMCB positions. The advice algorithm takes into account all of Pharmacyte Biotech's available fundamental, technical, and predictive indicators you will find on this site.
  
Refresh
The advice is provided from Pharmacyte Biotech's buy-and-hold perspective. Please check Pharmacyte Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Pharmacyte and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Pharmacyte Biotech.

Execute Pharmacyte Biotech Buy or Sell Advice

The Pharmacyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pharmacyte Biotech. Macroaxis does not own or have any residual interests in Pharmacyte Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pharmacyte Biotech's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Pharmacyte BiotechBuy Pharmacyte Biotech
Buy

Volatility

RiskyDetails

Hype Condition

Under hypedDetails

Current Valuation

Fairly ValuedDetails

Odds of Distress

Close to AverageDetails

Economic Sensitivity

Follows the market closelyDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

UnavailableDetails
For the selected time horizon Pharmacyte Biotech has a Risk Adjusted Performance of 0.062, Jensen Alpha of 0.2559, Total Risk Alpha of 0.5401, Sortino Ratio of 0.1018 and Treynor Ratio of 0.1668
We provide trade recommendations to complement the recent expert consensus on Pharmacyte Biotech. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Pharmacyte Biotech is not overpriced, please check all Pharmacyte Biotech fundamentals, including its cash and equivalents, cash flow from operations, and the relationship between the price to earning and debt to equity . Please also confirm Pharmacyte Biotech number of shares shorted to check out your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Pharmacyte Biotech Trading Alerts and Improvement Suggestions

Pharmacyte Biotech has very high historical volatility over the last 90 days
Net Loss for the year was (3.78 M) with profit before overhead, payroll, taxes, and interest of 0.
Pharmacyte Biotech currently holds about 86.64 M in cash with (3.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.streetinsider.com: Iroquois Issues Open Letter to Board of PharmaCyte Biotech - StreetInsider.com

Pharmacyte Biotech current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pharmacyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pharmacyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Recommendation Mean3.00
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Pharmacyte Biotech Returns Distribution Density

The distribution of Pharmacyte Biotech's historical returns is an attempt to chart the future uncertainty of Pharmacyte Biotech's future price movements. The chart of the probability distribution of Pharmacyte Biotech stock daily returns describes the distribution of returns around its average expected value. We use Pharmacyte Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pharmacyte Biotech returns is essential to provide solid investment advice for Pharmacyte Biotech stock.
Mean Return0.14Value At Risk-4.26
Potential Upside6.76Standard Deviation3.29
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pharmacyte Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Pharmacyte Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Pharmacyte Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pharmacyte Biotech backward and forwards among themselves. Pharmacyte Biotech's institutional investor refers to the entity that pools money to purchase Pharmacyte Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Sabby Management LlcCommon Shares1.3 M2.9 M
Shay Capital LlcCommon Shares944.7 K2.2 M
Vanguard Group IncCommon Shares614.6 K1.4 M
Equitec Proprietary Markets LlcCommon Shares309.3 K711 K
Geode Capital Management LlcCommon Shares171.5 K394 K
Ayrton Capital LlcCommon Shares153.1 K352 K
Price T Rowe Associates IncCommon Shares78.1 K180 K
Sabby Management LlcPut Options687158 K
Susquehanna International Group LlpCall Options43 K99 K
Note, although Pharmacyte Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pharmacyte Biotech Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pharmacyte Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pharmacyte Biotech stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pharmacyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.26
β
Beta against DOW0.76
σ
Overall volatility
3.27
Ir
Information ratio 0.09

Pharmacyte Biotech Volatility Alert

Pharmacyte Biotech currently demonstrates below-average downside deviation. It has Information Ratio of 0.09 and Jensen Alpha of 0.26. However, we advise investors to further question Pharmacyte Biotech expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pharmacyte Biotech's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pharmacyte Biotech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Pharmacyte Biotech Implied Volatility

Pharmacyte Biotech's implied volatility exposes the market's sentiment of Pharmacyte Biotech stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pharmacyte Biotech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pharmacyte Biotech stock will not fluctuate a lot when Pharmacyte Biotech's options are near their expiration.

Pharmacyte Biotech Fundamentals Vs Peers

Comparing Pharmacyte Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pharmacyte Biotech's direct or indirect competition across all of the common fundamentals between Pharmacyte Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pharmacyte Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pharmacyte Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Pharmacyte Biotech by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Pharmacyte Biotech to competition
FundamentalsPharmacyte BiotechPeer Average
Return On Equity(7.63) %(0.31) %
Return On Asset(4.89) %(0.14) %
Current Valuation(38.36 M)16.62 B
Shares Outstanding20.72 M571.82 M
Shares Owned by Insiders3.76 %10.09 %
Shares Owned by Institutions21.76 %39.21 %
Number of Shares Shorted477.01 K4.71 M
Price to Earning(5.35) X28.72 X
Price to Book0.50 X9.51 X
Net Income(3.78 M)570.98 M
Cash and Equivalents86.64 M2.7 B
Cash per Share4.18 X5.01 X
Total Debt21.46 K5.32 B
Debt to Equity0.003 %48.70 %
Current Ratio141.63 X2.16 X
Book Value Per Share4.45 X1.93 K
Cash Flow from Operations(3.87 M)971.22 M
Short Ratio0.56 X4.00 X
Earnings Per Share(0.67) X3.12 X
Number of Employees418.84 K
Beta0.01-0.15
Market Capitalization45.99 M19.03 B
Total Asset6.73 M29.47 B
Retained Earnings(86.7 M)9.33 B
Working Capital1.15 M1.48 B
Current Asset1.6 M9.34 B
Current Liabilities449 K7.9 B
   Pharmacyte Biotech exotic insider transaction detected [view details]

Pharmacyte Biotech Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pharmacyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution2123.48
Daily Balance Of Power(0.42)
Rate Of Daily Change0.98
Day Median Price2.24
Day Typical Price2.23
Market Facilitation Index0.0
Price Action Indicator(0.045)

About Pharmacyte Biotech Buy or Sell Advice

When is the right time to buy or sell Pharmacyte Biotech? Buying financial instruments such as Pharmacyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Pharmacyte Biotech investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Pharmacyte Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cars Thematic Idea Now

Cars
Cars Theme
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 30 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
View All  Next Launch Cars
Please check Pharmacyte Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Pharmacyte Biotech information on this page should be used as a complementary analysis to other Pharmacyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Pharmacyte Stock analysis

When running Pharmacyte Biotech price analysis, check to measure Pharmacyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacyte Biotech is operating at the current time. Most of Pharmacyte Biotech's value examination focuses on studying past and present price action to predict the probability of Pharmacyte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pharmacyte Biotech's price. Additionally, you may evaluate how the addition of Pharmacyte Biotech to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Pharmacyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacyte Biotech. If investors know Pharmacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacyte Biotech is measured differently than its book value, which is the value of Pharmacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Pharmacyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacyte Biotech's market value can be influenced by many factors that don't directly affect Pharmacyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Pharmacyte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.